Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19
2020-001448-24Phase 3Unknown
- Sponsor
- University of Birmingham
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of lopinavir + ritonavir and hydroxychloroquine in coronavirus disease 2019 (COVID-19) and pneumonia, sponsored by University of Birmingham. Primary endpoint: Pulmonary complications. Status: unknown.
02
Drugs
lopinavir + ritonavirhydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on 2020-001448-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001448-24.